|
1
|
Yardley DA, Brufsky A, Coleman RE, Conte
PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A,
et al: Phase II/III weekly nab-paclitaxel plus gemcitabine or
carboplatin versus gemcitabine/carboplatin as first-line treatment
of patients with metastatic triple-negative breast cancer (the
tnAcity study): Study protocol for a randomized controlled trial.
Trials. 17:632016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
von Minckwitz G and Martin M: Neoadjuvant
treatments for triple-negative breast cancer (TNBC). Ann Oncol. 23
Suppl 6:vi35–vi39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hatzis C, Symmans WF, Zhang Y, Gould RE,
Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar
AB, et al: Relationship between complete pathologic response to
neoadjuvant chemotherapy and survival in triple-negative breast
cancer. Clin Cancer Res. 22:26–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Song IH, Heo SH, Bang WS, Park HS, Park
IA, Kim YA, Park SY, Roh J, Gong G and Lee HJ: Predictive value of
tertiary lymphoid structures assessed by high endothelial venule
counts in the neoadjuvant setting of triple-negative breast cancer.
Cancer Res Treat. 49:399–407. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vici P, Di Benedetto A, Ercolani C,
Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R,
Botti C, et al: Predictive significance of DNA damage and repair
biomarkers in triple-negative breast cancer patients treated with
neoadjuvant chemotherapy: An exploratory analysis. Oncotarget.
6:42773–42780. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Humbert O, Riedinger JM, Charon-Barra C,
Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C,
Fumoleau P, Cochet A, et al: Identification of biomarkers including
18FDG-PET/CT for early prediction of response to
neoadjuvant chemotherapy in triple-negative breast cancer. Clin
Cancer Res. 21:5460–5468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang L, Ma X, He Y, Yuan C, Chen Q, Li G
and Chen X: Sirtuin 5: A review of structure, known inhibitors and
clues for developing new inhibitors. Sci China Life Sci.
60:249–256. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vellinga TT, Borovski T, de Boer VC,
Fatrai S, van Schelven S, Trumpi K, Verheem A, Snoeren N, Emmink
BL, Koster J, et al: SIRT1/PGC1α-dependent increase in oxidative
phosphorylation supports chemotherapy resistance of colon cancer.
Clin Cancer Res. 21:2870–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bai L, Lin G, Sun L, Liu Y, Huang X, Cao
C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis
and promotes metastasis of non-small cell lung cancer via the
ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kugel S, Sebastián C, Fitamant J, Ross KN,
Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, et al:
SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell.
165:1401–1415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartosch C, Monteiro-Reis S, Almeida-Rios
D, Vieira R, Castro A, Moutinho M, Rodrigues M, Graça I, Lopes JM
and Jerónimo C: Assessing sirtuin expression in endometrial
carcinoma and non-neoplastic endometrium. Oncotarget. 7:1144–1154.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Temel M, Koç MN, Ulutaş S and Göğebakan B:
The expression levels of the sirtuins in patients with BCC. Tumour
Biol. 37:6429–6435. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lai CC, Lin PM, Lin SF, Hsu CH, Lin HC, Hu
ML, Hsu CM and Yang MY: Altered expression of SIRT gene family in
head and neck squamous cell carcinoma. Tumour Biol. 34:1847–1854.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Igci M, Kalender ME, Borazan E, Bozgeyik
I, Bayraktar R, Bozgeyik E, Camci C and Arslan A: High-throughput
screening of Sirtuin family of genes in breast cancer. Gene.
586:123–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Horak CE, Pusztai L, Xing G, Trifan OC,
Saura C, Tseng LM, Chan S, Welcher R and Liu D: Biomarker analysis
of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone
or Paclitaxel in early-stage breast cancer. Clin Cancer Res.
19:1587–1595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peng S, Xu Q, Ling XB, Peng X, Du W and
Chen L: Molecular classification of cancer types from microarray
data using the combination of genetic algorithms and support vector
machines. FEBS Lett. 555:358–362. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Caudle AS, Yu TK, Tucker SL, Bedrosian I,
Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt
KK, Buchholz TA, et al: Local-regional control according to
surrogate markers of breast cancer subtypes and response to
neoadjuvant chemotherapy in breast cancer patients undergoing
breast conserving therapy. Breast Cancer Res. 14:R832012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Chen S, Chen C, Di G, Liu G, Wu J
and Shao Z: Pathological complete response as a surrogate for
relapse-free survival in patients with triple negative breast
cancer after neoadjuvant chemotherapy. Oncotarget. 8:18399–18408.
2017.PubMed/NCBI
|
|
22
|
Kumar S and Lombard DB: Mitochondrial
sirtuins and their relationships with metabolic disease and cancer.
Antioxid Redox Signal. 22:1060–1077. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakagawa T, Lomb DJ, Haigis MC and
Guarente L: SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and
regulates the urea cycle. Cell. 137:560–570. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Polletta L, Vernucci E, Carnevale I,
Arcangeli T, Rotili D, Palmerio S, Steegborn C, Nowak T,
Schutkowski M, Pellegrini L, et al: SIRT5 regulation of
ammonia-induced autophagy and mitophagy. Autophagy. 11:253–270.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo W, Wang Y, Wang Z, Wang YP and Zheng
H: Inhibiting autophagy increases epirubicin's cytotoxicity in
breast cancer cells. Cancer Sci. 107:1610–1621. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kong JN, He Q, Wang G, Dasgupta S, Dinkins
MB, Zhu G, Kim A, Spassieva S and Bieberich E: Guggulsterone and
bexarotene induce secretion of exosome-associated breast cancer
resistance protein and reduce doxorubicin resistance in MDA-MB-231
cells. Int J Cancer. 137:1610–1620. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hanna S and El-Sibai M: Signaling networks
of Rho GTPases in cell motility. Cell Signal. 25:1955–1961. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wojnacki J, Quassollo G, Marzolo MP and
Cáceres A: Rho GTPases at the crossroad of signaling networks in
mammals: Impact of Rho-GTPases on microtubule organization and
dynamics. Small GTPases. 5:e284302014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hervé JC and Bourmeyster N: Rho GTPases at
the crossroad of signaling networks in mammals. Small GTPases.
6:43–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Amano M, Kaneko T, Maeda A, Nakayama M,
Ito M, Yamauchi T, Goto H, Fukata Y, Oshiro N, Shinohara A, et al:
Identification of Tau and MAP2 as novel substrates of Rho-kinase
and myosin phosphatase. J Neurochem. 87:780–790. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li ZH, Xiong QY, Tu JH, Gong Y, Qiu W,
Zhang HQ, Wei WS, Hou YF and Cui WQ: Tau proteins expressions in
advanced breast cancer and its significance in taxane-containing
neoadjuvant chemotherapy. Med Oncol. 30:5912013. View Article : Google Scholar : PubMed/NCBI
|
